Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis’ SMA Gene Therapy Treatment Approved by FDA, Priced at $2.125 Million

The U.S. Food and Drug Administration approved Zolgensma, a gene therapy that Novartis called a life-changing medicine, for children younger than 2 years of age who have been diagnosed with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 gene.

Read More »

Eli Lilly’s Generic Insulin Hits Market at Half the Price of Branded Counterpart

Indianapolis-based Eli Lilly announced that the company’s Lispro Injection, an authorized generic version of the life-saving insulin Humalog, is available at pharmacies at a 50 percent lower list price.

Read More »

Novartis gets approval to sell Kymriah in Japan for $306,000

A Japanese government panel approved a price of 33.5 million yen ($305,800) for Novartis’ cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment.

Read More »

NHS England, Biogen reach deal on pricey drug for deadly disorder

England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.

Read More »

Novartis vows to fight U.S. price-fixing claims against Sandoz unit

Novartis said claims of price fixing against the drugmaker’s Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit.

Read More »

U.S. finalizes rule requiring drug prices in TV spots

The Trump administration will require drugmakers to disclose the list price of prescription drugs in DTC TV advertisements, part of the government’s efforts to lower costs for U.S. consumers.

Read More »

Senators tell drug company executives pricing is ‘morally repugnant’

U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines.

Read More »

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc. – rebuked by U.S. Senator Bernie Sanders for high drug prices – defended the company’s $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

Read More »

U.S. top court rejects Maryland bid to revive drug price-gouging law

The U.S. Supreme Court rejected Maryland’s bid to revive a law aimed at preventing price gouging by pharmaceutical companies, dealing a setback to the power of states to rein in prescription drug costs.

Read More »

House Ways and Means Committee Holds Hearing on Drug Prices

The rising costs of prescription medicine took center stage during a hearing held by the Ways and Means Committee in the U.S. House of Representatives.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom